Social anxiety disorder in the West and in the East

Annals of Clinical Psychiatry

Volumn 21, Issue 2, 2009, Pages 109-117

  Stein, Dan J ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cultural concepts; Selective serotonin reuptake inhibitors; Social anxiety disorder; Taijin kyofusho

Indexed keywords

ADULT; ASIA; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY; ETHNIC GROUP; ETHNOLOGY; EUROPE; HUMAN; NORTH AMERICA; PERSONALITY DISORDER; PHENOTYPE; PHOBIA; PREVALENCE; REVIEW; STATISTICS;

ADULT; ASIA; CHILD; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY; ETHNIC GROUPS; EUROPE; HUMANS; NORTH AMERICA; PERSONALITY DISORDERS; PHENOTYPE; PHOBIC DISORDERS; PREVALENCE;

EID: 70349576904     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Magee WJ, Eaton WW, Wittchen HU, et al. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:159-168. (Pubitemid 26049391)
2. Fehm L, Pelissolo A, Furmark T, et al. Size and burden of social phobia in Europe. Eur Neuropsychopharmacol. 2005;15:453-462. (Pubitemid 40949552)
3. Ballenger JC, Davidson JA, Lecrubier Y, et al. Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59:54-60. (Pubitemid 28487516)
4. Wakefi eld JC, Horwitz AV, Schmitz MF. Are we over-pathologizing the socially anxious? Social phobia from a harmful dysfunction perspective. Can J Psychiatry. 2005;50:317-319.
5. Muller JE, Koen L, Stein DJ. The spectrum of social anxiety disorders. In: Bandelow B, Stein DJ, eds. Social anxiety disorder. New York, NY: Marcel Dekker; 2004.
6. Matsunaga H, Kiriike N, Matsui T, et al. Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors? Int J Neuropyschopharmacol. 2001;4:231-237. (Pubitemid 34101519)
7. Kirmayer LJ. The place of culture in psychiatric nosology: taijin kyofusho and DSM-III-R. J Nerv Ment Dis. 1991;179:19-28.
8. Ono Y, Young J. Taijin Kyofusho in Japan: Social phobia or culture-bound syndrome? Psychiatric Networks. 2000;3:47-58.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
10. Merikangas KR, Avenevoli S, Acharyya S, et al. The spectrum of social phobia in the Zurich Cohort Study of Young Adults. Biol Psychiatry. 2002;51:81-91. (Pubitemid 34093796)
11. Chavira DA, Stein MB. The shyness spectrum. CNS Spectr. 1999;4:20-26.
12. Kleinknecht RA, Dinnel DL, Kleinknecht EE, et al. Cultural factors in social anxiety: a comparison of social phobia symptoms and Taijin Kyofusho. J Anxiety Disord. 1997;11:157-177. (Pubitemid 27246576)
13. Maeda F, Nathan JH. Understanding taijin kyofusho through its treatment, Morita therapy. J Psychosom Res. 1999;46:525-530. (Pubitemid 29342445)
14. Kinoshita Y, Chen J, Rapee RM, et al. Cross-cultural study of conviction subtype Taijin kyofu: proposal and reliability of Nagoya-Osaka diagnostic criteria for social anxiety disorder. J Nerv Ment Dis. 2008;196:307-313. (Pubitemid 351548731)
15. Chang SC. Social anxiety (phobia) and east Asian culture. Depress Anxiety. 1997;5:115-120. (Pubitemid 28079911)
16. Takahashi T. Social phobia syndrome in Japan. Compr Psychiatry. 1989;30:45-52. (Pubitemid 19037422)
17. Ono Y, Yoshimura K, Yamauchi K, et al. Taijin Kyofusho in a Japanese community population. Transcult Psychiatry. 2001;38:506-514. (Pubitemid 34023617)
18. Liebowitz MR. Social phobia. In: Ban TA, Pichot P, Poldinger W, eds. Modern problems of pharmacopsychiatry. Basel, Switzerland; 1987.
19. Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371:1115-1125. (Pubitemid 351418007)
20. Schwartz CE, Wright CI, Shin LM, et al. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science. 2003;5627:1952-1953. (Pubitemid 36734603)
21. Smoller JW, Rosenbaum JF, Biederman J, et al. Association of a genetic marker at the corticotropin-releasing hormone locus with behavioral inhibition. Biol Psychiatry. 2003;54:1376-1381. (Pubitemid 37522161)
22. Stein DJ. Cognitive-aff ective neuroscience of depression and anxiety disorders. London, UK: Martin Dunitz; 2003.
23. Stein DJ, Westenberg HG, Liebowitz MR. Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry. J Clin Psychiatry. 2002;63(suppl 6):12-19. (Pubitemid 34438945)
24. Nesse RM, Williams GC. Why we get sick: The new science of Darwinian medicine. New York, NY: Vintage Books; 1994.
25. Darwin C. The Expression of Emotion in Man and Animals. London, UK: John Murray; 1872.
26. Stein DJ, Bouwer C. A neuro-evolutionary approach to the anxiety disorders. J Anxiety Disord. 1997;11:409-429. (Pubitemid 27397166)
27. Stein DJ. Advances in understanding the anxiety disorders: the cognitive-neuroscience of "false alarms." Ann Clin Psychiatry. 2006;18:173-182. (Pubitemid 44576439)
28. Liebowitz MR, Fyer AJ, Gorman JM, et al. Phenelzine in social phobia. J Clin Psychopharmacol. 1986;6:93-98. (Pubitemid 16142445)
29. Davidson JR, Tupler LA, Potts NL. Treatment of social phobia with benzodiazepines. J Clin Psychiatry. 1994;55(suppl):28-32.
30. van Vliet IM, den Boer JA, Westenberg H. Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fl uvoxamine. Psychopharmacol. 1994;115:128-134.
31. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999;156:756-760. (Pubitemid 29220075)
32. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708-713. (Pubitemid 28405295)
33. Baldwin D, Bobes J, Stein DJ, et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999;175:120-126. (Pubitemid 29359373)
34. Allgulander C. Paroxetine in social anxiety disorder: a randomised placebo-controlled study. Acta Psychiatr Scand. 1999;100:193-198.
35. van Ameringen MA, Lane RM, Walker JR, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158:275-281.
36. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152:1368-1371.
37. Kasper S, Stein DJ, Loft H, et al. Escitalopram is eff ective and well tolerated in the treatment of social anxiety disorder: a randomised, placebo-controlled, fl exible-dose study. Br J Psychiatry. 2005;186:222-226.
38. Lader M, Stender K, Bürger V, et al. Effi cacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: a randomised, double-blind, placebo-controlled, fi xed-dose study. Depress Anxiety. 2004;19:241-248. (Pubitemid 39014144)
39. Mangano RM. Treating social anxiety disorder with venlafaxine extended release. Eur Neuropsychopharmacol. 2002;12:358.
40. van der Linden GJ, Stein DJ, van Balkom AJ. The effi cacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a metaanalysis of randomized controlled trials. Int Clin Psychopharmacol. 2000;15(suppl 2):15-24.
41. Blanco C, Schneier FR, Schmidt AB, et al. Pharmacological treatment of social anxiety disorder: a metaanalysis. Depress Anxiety. 2003;18:29-40. (Pubitemid 37012933)
42. Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social anxiety disorder. Cochrane Database Syst Rev. 2004;CD001206.
43. Stein DJ, Versiani M, Hair T, et al. Effi cacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study. Arch Gen Psychiatry. 2002;59:1111-1118. (Pubitemid 35424021)
44. Walker JR, van Ameringen MA, Swinson R, et al. Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol. 2000;20:636-644.
45. Randall CL, Johnson MR, Thevos AK, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety. 2001;14:255-262. (Pubitemid 34013800)
46. March JS, Entusah AR, Rynn M, et al. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry. 2007;62:1149-1154. (Pubitemid 350029720)
47. Blomhoff S, Haug TT, Hellström K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179:23-30.
48. Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006;63:298-304. (Pubitemid 43345354)
49. Bandelow B, Zohar J, Hollander E, et al, and the World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry. 2002;3:171-199.
50. Shindo M, Shioiri T, Kuwabara H, et al. Clinical features and treatment outcome in Japanese patients with social anxiety disorder: chart review study. Psychiatry Clin Neurosci. 2006;60:410-416. (Pubitemid 44060795)
51. Kobayashi N, Kurauchi S, Sawamura T, et al. The eff ect of paroxetine on Taijinkyofusho: a report of three cases. Psychiatry. 2003;66:262-267. (Pubitemid 37296753)
52. Nagata T, van Vliet I, Yamada H, et al. An open trial of paroxetine for the "off ensive subtype" of taijin kyofusho and social anxiety disorder. Depress Anxiety. 2006;23:168-174. (Pubitemid 43727147)
53. Nagata T, Oshima J, Wada A, et al. Open trial of milnacipran for Taijin-Kyofusho in Japanese patients with social anxiety disorder. International Journal of Psychiatry in Clinical Practice. 2003;7:107-112. (Pubitemid 36917073)
54. Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2007;10:263-274.
55. Kuzma JM, Black DW. Integrating pharmacotherapy and psychotherapy in the management of anxiety disorders. Curr Psychiatry Rep. 2004;6:268-273. (Pubitemid 39173542)
56. Kitanishi K, Mori A. Morita therapy: 1919 to 1995. Psychiatry Clin Neurosci. 1995;49:245-254. (Pubitemid 26013054)
57. Stein DJ, Matsunaga H. Cross-cultural aspects of social anxiety disorder. Psychiatr Clin North Am. 2001;24:773-782. (Pubitemid 33054918)
58. Stein DJ, Williams D. Cross-cultural aspects of anxiety disorders. In: Stein DJ, Hollander E. The American Psychiatric Publishing textbook of anxiety disorders. Washington, DC: American Psychiatric Publishing, Inc.; 2002.
59. Stein DJ. Cross-cultural psychiatry and the DSM-IV. Compr Psychiatry. 1993;34:322-329. (Pubitemid 23277070)
60. Prince R, Tcheng-Laroche F. Culture-bound syndromes and international disease classifi cations. Cult Med Psychiatry. 1987;11:3-20.
61. Boas F. Recent anthropology. Science. 1943;98:311- 314.
62. Kleinman A. Rethinking psychiatry: From cultural category to personal experience. New York, NY: Free Press; 1988.
63. Eisen JL, Phillips KA, Coles ME, et al. Insight in obsessive compulsive disorder and body dysmorphic disorder. Compr Psychiatry. 2004;45:10-15. (Pubitemid 38029969)
64. Lochner C, Stein DJ. Olfactory reference syndrome: diagnostic criteria and diff erential diagnosis. Postgrad Med. 2003;49:328-331. (Pubitemid 38714071)
65. Nakamura K, Kitanishi K, Miyake Y, et al. The neurotic versus delusional subtype of taijin-kyofusho: their DSM diagnoses. Psychiatry Clin Neurosci. 2002;56:595-601. (Pubitemid 35364592)
66. Suzuki K, Takei N, Iwata Y, et al. Do olfactory reference syndrome and Jiko-shu-kyofu (a subtype of Taijin-kyofu) share a common entity? Acta Psychiatr Scand. 2004;109:150-155. (Pubitemid 38186830)
67. Rector NA, Kocovski NL, Ryder AG. Social anxiety and the fear of causing discomfort to others. Cognitive Therapy and Research. 2006;30:279-296. (Pubitemid 44837132)
68. Kim J, Rapee RM, Gaston JF. Symptoms of off ensive type Taijin-Kyofusho among Australian social phobics. Depress Anxiety. 2008;25:601-608.
69. Clarvit SR, Schneier FR, Liebowitz MR. The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder. J Clin Psychiatry. 1996;57:523-527. (Pubitemid 26412504)
70. Choy Y, Schneier FR, Heimberg RG, et al. Features of the off ensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder. Depress Anxiety. 2008;25:230-240. (Pubitemid 351499902)
71. Ono Y, Yoshimura K, Sueoko R, et al. Avoidant personality disorder and taijin kyoufu: sociocultural implications of the WHO/ADAMHA International Study of Personality Disorders in Japan. Acta Psychiatr Scand. 1996;93:172-176. (Pubitemid 26141606)
72. Emery NJ. The eyes have it: the neuroethology, function and evolution of social gaze. Neurosci Biobehav Rev. 2000;24:581-604. (Pubitemid 30625127)
73. Stein DJ, Le Roux L, Bouwer C, et al. Is olfactory reference syndrome on the obsessive-compulsive spectrum?: Two cases and a discussion. J Neuropsychiatry Clin Neurosci. 1998;10:96-99. (Pubitemid 28135130)
74. Phillips KA. Body dysmorphic disorder: clinical aspects and treatment strategies. Bull Menninger Clin. 1998;62(4 suppl A):33-48.